Financials Vaxcyte, Inc.

Equities

PCVX

US92243G1085

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 11:44:33 2026-03-09 am EDT			5-day change	1st Jan Change
58.20 ^USD	-1.84%		-5.24%	+27.29%

Feb. 25	Analyst recommendations: IBM, Axon, Caterpillar, Fair Isaac, Gilead…
Feb. 24	Vaxcyte, Inc., Q4 2025 Earnings Call, Feb 24, 2026

Projected Income Statement: Vaxcyte, Inc.

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Net sales ¹	-	-	-	-	-	-	27.38	224.6
Change	-	-	-	-	-	-	-	720.09%
EBITDA ¹	-101.9	-229.7	-464.9	-562.5	-	-1,132	-940.9	-
Change	-	-125.46%	-102.41%	-21.01%	-	-	16.88%	-
EBIT ¹	-103.7	-232.3	-468	-569.5	-923.7	-1,167	-1,104	-916.5
Change	-	-124.03%	-101.52%	-21.69%	-62.18%	-26.34%	5.36%	17.02%
Interest Paid	-	-0.002	-	-	-	-	-	-
Earnings before Tax (EBT) ¹	-100.1	-223.5	-402.3	-463.9	-766.6	-1,057	-1,035	-843.6
Change	-	-123.31%	-80%	-15.33%	-65.25%	-37.83%	2.07%	18.47%
Net income ¹	-100.1	-223.5	-402.3	-463.9	-766.6	-1,121	-1,168	-1,084
Change	-	-123.31%	-80%	-15.33%	-65.25%	-46.22%	-4.2%	7.2%
Announcement Date	2/28/22	2/27/23	2/27/24	2/25/25	2/24/26	-	-	-

¹USD in Million

Estimates

Fiscal Period: December	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3	2026 Q4
Net sales ¹	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA ¹	-	-	-	-	-	-	-	-	-	-	-	-195.8	-	-	-138.1	-159.3	-	-223.3	-239.3	-	-285.1	-294.2	-304.7	-
Change	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-15.32%	-	-	-7.15%	-	-	-3.21%	-3.57%	-
EBIT ¹	-23.14	-23.73	-26.95	-29.85	-39.22	-47.89	-58.58	-86.57	-71.19	-87.15	-113	-196.7	-114.5	-153	-139.9	-162.2	-180.8	-226.2	-242.4	-274.3	-281.1	-290.2	-299.4	-304
Change	-	-2.54%	-13.57%	-10.74%	-31.41%	-22.09%	-22.33%	-47.79%	17.77%	-22.41%	-29.7%	-74.01%	41.8%	-33.64%	8.54%	-15.9%	-11.48%	-25.13%	-7.14%	-13.16%	-2.48%	-3.23%	-3.2%	-1.51%
Charge d'intérêts	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings before Tax (EBT) ¹	-21.22	-23.68	-26.62	-28.56	-38.99	-48.53	-57.92	-78.05	-60.46	-68.34	-92.66	-180.8	-95.02	-128.7	-103.1	-137.1	-140.7	-166.6	-212.8	-246.5	-257	-263.5	-273.8	-282.2
Change	-	-11.59%	-12.4%	-7.32%	-36.49%	-24.49%	-19.34%	-34.76%	22.53%	-13.03%	-35.59%	-95.11%	47.44%	-35.45%	19.87%	-32.93%	-2.65%	-18.37%	-27.77%	-15.82%	-4.25%	-2.54%	-3.91%	-3.06%
Net income ¹	-21.22	-23.68	-26.62	-28.56	-38.99	-48.53	-57.92	-78.05	-60.46	-68.34	-92.66	-180.8	-95.02	-128.7	-103.1	-137.1	-140.7	-166.6	-212.8	-246.5	-266.1	-278.3	-295.6	-311.6
Change	-	-11.59%	-12.4%	-7.32%	-36.49%	-24.49%	-19.34%	-34.76%	22.53%	-13.03%	-35.59%	-95.11%	47.44%	-35.45%	19.87%	-32.93%	-2.65%	-18.37%	-27.77%	-15.82%	-7.94%	-4.59%	-6.2%	-5.42%
Announcement Date	5/11/21	8/11/21	11/10/21	2/28/22	5/9/22	8/8/22	11/7/22	2/27/23	5/8/23	8/8/23	11/6/23	2/27/24	5/8/24	8/6/24	11/5/24	2/25/25	5/7/25	8/6/25	11/4/25	2/24/26	-	-	-	-

¹USD in Million

Estimates

Forecast Balance Sheet: Vaxcyte, Inc.

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Net Debt ¹	-	-	-	-1,747	-	-472	-556	-
Change	-	-	-	-	-	-	-17.8%	-
Announcement Date	2/28/22	2/27/23	2/27/24	2/25/25	2/24/26	-	-	-

¹USD in Million

Estimates

Cash Flow Forecast: Vaxcyte, Inc.

Fiscal Period: December	2021	2022	2023	2024	2026	2027	2028
CAPEX ¹	6.555	5.848	16.06	22.43	14.5	11	13.5
Change	-	-10.79%	174.66%	39.63%	-	-24.14%	22.73%
Free Cash Flow (FCF) ¹	-127.9	-66.37	-312.9	-475.1	-1,058	-1,099	-793.5
Change	-	48.13%	-371.39%	-51.85%	-	-3.88%	27.8%
Announcement Date	2/28/22	2/27/23	2/27/24	2/25/25	-	-	-

¹USD in Million

Estimates

Forecast Financial Ratios: Vaxcyte, Inc.

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Profitability
EBITDA Margin (%)	-	-	-	-	-	-	-3,436.19%	-
EBIT Margin (%)	-	-	-	-	-	-	-4,033.09%	-408.11%
EBT Margin (%)	-	-	-	-	-	-	-3,778.73%	-375.65%
Net margin (%)	-	-	-	-	-	-	-4,265.52%	-482.67%
FCF margin (%)	-	-	-	-	-	-	-4,013.39%	-353.35%
FCF / Net Income (%)	127.85%	29.7%	77.77%	102.4%	-	94.39%	94.09%	73.21%
Profitability
ROA	-	-	-	-	-	-	-	-
ROE	-17.71%	-36.12%	-36.67%	-20.41%	-	-39.46%	-	-
Financial Health
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Debt / Free cash flow	-	-	-	-	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	-	-	-	-	-	-	40.17%	6.01%
CAPEX / EBITDA (%)	-6.43%	-2.55%	-3.46%	-3.99%	-	-1.28%	-1.17%	-
CAPEX / FCF (%)	-5.12%	-8.81%	-5.13%	-4.72%	-	-1.37%	-1%	-1.7%
Items per share
Cash flow per share ¹	-2.338	-2.63	-2.988	-3.71	-	-4.944	-4.242	-
Change	-	-12.47%	-13.62%	-24.18%	-	-	14.19%	-
Dividend per Share ¹	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
Book Value Per Share ¹	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
EPS ¹	-1.93	-3.44	-4.14	-3.8	-5.63	-7.385	-7.353	-6.363
Change	-	-78.24%	-20.35%	8.21%	-48.16%	-31.17%	0.44%	13.46%
Nbr of stocks (in thousands)	52,785	78,980	95,154	124,637	130,906	143,920	143,920	143,920
Announcement Date	2/28/22	2/27/23	2/27/24	2/25/25	2/24/26	-	-	-